Grindeks Group companies have ambitious goals and long-term plans, and participation in such exhibitions are an opportunity to reach them and strengthen Group’s international presence. During the exhibition, Grindeks will present Group’s final dosage forms and active pharmaceutical ingredients product range. Grindeks has been actively working to diversify oncological medicines product range, and recently added medicines will be presented during the exhibition.

Although the Group’s products are exported to more than 85 countries, Grindeks plans to attract new distributors and manufacturers for long-term cooperation and business development in other markets, including, strategically important European Union and South East Asia region markets. During the exhibition, meetings with existing partners will be held to discuss wider cooperation opportunities.

Group’s subsidiary Kalceks specializes in generics for the hospital segment, and company’s main task in the exhibition will be business relationship establishment with new cooperation partners from countries where Kalceks products are not available yet, especially – European Union countries and Northern America market. Company products are being exported to more than 50 countries, and in the nearest time, the company plans to increase the number of its cooperation partners and expand geographically.

Kalceks has an important role in Latvia pharmaceutical market, and the company is working to strengthen its’ position internationally. Among company products are such medicines as Dexmedetomidine, Rocuronium, and each year 7-8 products are added to the product range. Kalceks is one of the oldest pharmaceuticals companies in the Baltic States that specializes in parenteral medicine manufacturing.